EUVIMEDEUVIMED entdecken
LeserbriefKommentarOpen Access

Pembrolizumab in HER2-Positive Gastric Cancer

Yelena Y Janjigian, Akihito Kawazoe iD, Yuxian Bai, Jianming Xu, Sara Lonardi, Jean Phillipe Metges, Patricio Yañez, Lucjan S Wyrwicz, Lin Shen, Yuriy Ostapenko, Mehmet Bilici, Hyun Cheol Chung und 14 weitere

New England Journal of Medicine · 10.10.2024 · 391 (14) · 1360-1362

DOI: 10.1056/nejmc2408121 ↗

Kurz gefasst

Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 10.10.2024. Verfasst von Yelena Y Janjigian und 25 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, NY janjigiy@mskcc.org. Hauptthemen laut MEDLINE: Adenocarcinoma, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 2 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, Merck & Co., Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalErb-b2 Receptor Tyrosine KinasesStomach NeoplasmsAgedFemaleHumansMaleMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsDouble-Blind MethodEsophagogastric JunctionProgression-Free SurvivalTrastuzumabMulticenter Studies as TopicRandomized Controlled Trials as TopicClinical Trials, Phase III as Topic

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalERBB2 protein, humanpembrolizumabErb-b2 Receptor Tyrosine KinasesTrastuzumab

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, New York, NY janjigiy@mskcc.org.
  • National Cancer Hospital East, Kashiwa, Japan.
  • Harbin Medical University Cancer Hospital, Harbin, China.
  • Fifth Medical Center of the People's Liberation Army, Beijing, China.
  • Istituto Oncologico Veneto, Padua, Italy.
  • University Hospital of Brest, Brest, France.

ORCID-Profile: Akihito Kawazoe, Kohei Shitara

Förderung

  • NCI NIH HHS
  • NIH HHS
  • Merck & Co., Inc
  • Memorial Sloan Kettering Cancer Center National Institutes of Health/National Cancer Institute Cancer Center Support Grant

Zitieren

APA

Janjigian, Y. Y., Kawazoe, A., Bai, Y., Xu, J., Lonardi, S., Metges, J. P., Yañez, P., Wyrwicz, L. S., Shen, L., Ostapenko, Y., Bilici, M., Chung, H. C., Shitara, K., Qin, S., Van Cutsem, E., Tabernero, J., Luo, S., Mahave, M., Tang, Y., …, & Rha, S. Y. (2024). Pembrolizumab in HER2-Positive Gastric Cancer. New England Journal of Medicine, 391(14), 1360-1362. https://doi.org/10.1056/nejmc2408121

Vancouver

Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab in HER2-Positive Gastric Cancer. New England Journal of Medicine. 2024;391(14):1360-1362. doi:10.1056/nejmc2408121

BibTeX
@article{Janjigian2024,
  author = {Janjigian, Yelena Y and Kawazoe, Akihito and Bai, Yuxian and Xu, Jianming and Lonardi, Sara and Metges, Jean Phillipe and Yañez, Patricio and Wyrwicz, Lucjan S and Shen, Lin and Ostapenko, Yuriy and Bilici, Mehmet and Chung, Hyun Cheol and Shitara, Kohei and Qin, Shukui and Van Cutsem, Eric and Tabernero, Josep and Luo, Suxia and Mahave, Mauricio and Tang, Yong and Lowery, Maeve and Monteiro, Maria M F and Xu, Linzhi and Shih, Chie-Schin and Sharan, Kanu P and Bhagia, Pooja and Rha, Sun Young},
  title = {Pembrolizumab in HER2-Positive Gastric Cancer},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {14},
  pages = {1360--1362},
  doi = {10.1056/nejmc2408121}
}
Kostenlos starten →